Literature DB >> 28160356

Ferumoxytol vs. Gadolinium agents for contrast-enhanced MRI: Thoughts on evolving indications, risks, and benefits.

J Paul Finn1,2,3, Kim-Lien Nguyen2, Peng Hu1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28160356     DOI： 10.1002/jmri.25580

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN： 1053-1807            Impact factor:   5.119


× No keyword cloud information.
  18 in total

1.  Susceptibility weighted imaging and quantitative susceptibility mapping of the cerebral vasculature using ferumoxytol.

Authors:  Saifeng Liu; Jean-Christophe Brisset; Jiani Hu; E Mark Haacke; Yulin Ge
Journal:  J Magn Reson Imaging       Date:  2017-07-21       Impact factor: 4.813

2.  Quantitative comparison of delayed ferumoxytol T1 enhancement with immediate gadoteridol enhancement in high grade gliomas.

Authors:  Andrea Horváth; Csanad G Varallyay; Daniel Schwartz; Gerda B Toth; Joao P Netto; Ramon Barajas; Péter Várallyay; László Szidonya; Jenny Firkins; Emily Youngers; Rongwei Fu; Prakash Ambady; Péter Bogner; Edward A Neuwelt
Journal:  Magn Reson Med       Date:  2017-12-04       Impact factor: 4.668

3.  Measurements of cerebral blood volume using quantitative susceptibility mapping, R2 * relaxometry, and ferumoxytol-enhanced MRI.

Authors:  Leonardo A Rivera-Rivera; Tilman Schubert; Kevin M Johnson
Journal:  NMR Biomed       Date:  2019-09-04       Impact factor: 4.044

4.  Comparison of ferumoxytol-based cerebral blood volume estimates using quantitative R1 and R2* relaxometry.

Authors:  Leonardo A Rivera-Rivera; Tilman Schubert; Gesine Knobloch; Patrick A Turski; Oliver Wieben; Scott B Reeder; Kevin M Johnson
Journal:  Magn Reson Med       Date:  2017-11-02       Impact factor: 4.668

5.  Comparing the signal enhancement of a gadolinium based and an iron-oxide based contrast agent in low-field MRI.

Authors:  Jordy K van Zandwijk; Frank F J Simonis; Friso G Heslinga; Elfi I S Hofmeijer; Robert H Geelkerken; Bennie Ten Haken
Journal:  PLoS One       Date:  2021-08-17       Impact factor: 3.240

Review 6.  Performance of Cardiac MRI in Pediatric and Adult Patients with Fontan Circulation.

Authors:  Filippo Puricelli; Inga Voges; Peter Gatehouse; Michael Rigby; Cemil Izgi; Dudley J Pennell; Sylvia Krupickova
Journal:  Radiol Cardiothorac Imaging       Date:  2022-06-02

Review 7.  Whole-body magnetic resonance imaging: techniques and non-oncologic indications.

Authors:  Mary-Louise C Greer
Journal:  Pediatr Radiol       Date:  2018-08-04

8.  USPIOs as targeted contrast agents in cardiovascular magnetic resonance imaging.

Authors:  Yi Lu; Jenny Huang; Natalia V Neverova; Kim-Lien Nguyen
Journal:  Curr Cardiovasc Imaging Rep       Date:  2021-02-26

9.  Intermodality feature fusion combining unenhanced computed tomography and ferumoxytol-enhanced magnetic resonance angiography for patient-specific vascular mapping in renal impairment.

Authors:  Takegawa Yoshida; Kim-Lien Nguyen; Puja Shahrouki; William J Quinones-Baldrich; Peter F Lawrence; J Paul Finn
Journal:  J Vasc Surg       Date:  2019-11-14       Impact factor: 4.860

10.  Multicenter Safety and Practice for Off-Label Diagnostic Use of Ferumoxytol in MRI.

Authors:  Kim-Lien Nguyen; Takegawa Yoshida; Nikhita Kathuria-Prakash; Islam H Zaki; Csanad G Varallyay; Scott I Semple; Rola Saouaf; Cynthia K Rigsby; Sokratis Stoumpos; Kevin K Whitehead; Lindsay M Griffin; David Saloner; Michael D Hope; Martin R Prince; Mark A Fogel; Mark L Schiebler; Giles H Roditi; Aleksandra Radjenovic; David E Newby; Edward A Neuwelt; Mustafa R Bashir; Peng Hu; J Paul Finn
Journal:  Radiology       Date:  2019-10-22       Impact factor: 11.105
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.